|
1
|
Tang B, Yoo N, Vu M, Mamura M, Nam JS,
Ooshima A, Du Z, Desprez PY, Anver MR, Michalowska AM, Shih J,
Parks WT and Wakefield LM: Transforming growth factor-β can
suppress tumorigenesis through effects on the putative cancer stem
or early progenitor cell and committed progeny in a breast cancer
xenograft model. Cancer Res. 67:8643–8652. 2007.
|
|
2
|
Forrester E, Chytil A, Bierie B, Aakre M,
Gorska AE, Sharif-Afshar AR, Muller WJ and Moses HL: Effect of
conditional knockout of the type II TGF-β receptor gene in mammary
epithelia on mammary gland development and polyomavirus middle T
antigen induced tumor formation and metastasis. Cancer Res.
65:2296–2302. 2005.
|
|
3
|
Jakowlew SB: Transforming growth factor-β
in cancer and metastasis. Cancer Metastasis Rev. 25:435–457.
2006.
|
|
4
|
Galliher AJ, Neil JR and Schiemann WP:
Role of transforming growth factor-β in cancer progression. Future
Oncol. 2:743–763. 2006.
|
|
5
|
Talbot LJ, Bhattacharya SD and Kuo PC:
Epithelial-mesenchymal transition, the tumor microenvironment, and
metastatic behavior of epithelial malignancies. Int J Biochem Mol
Biol. 3:117–136. 2012.PubMed/NCBI
|
|
6
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: at the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Letterio JJ and Roberts AB: Regulation of
immune responses by TGF-β. Annu Rev Immunol. 16:137–161. 1998.
|
|
8
|
Wrzesinski SH, Wan YY and Flavell RA:
Transforming growth factor-beta and the immune response:
implications for anticancer therapy. Clin Cancer Res. 13:5262–5270.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang YA, Dukhanina O, Tang B, Mamura M,
Letterio JJ, MacGregor J, Patel SC, Khozin S, Liu ZY, Green J,
Anver MR, Merlino G and Wakefield LM: Lifetime exposure to a
soluble TGF-β antagonist protects mice against metastasis without
adverse side effects. J Clin Invest. 109:1607–1615. 2002.PubMed/NCBI
|
|
10
|
Frazier K, Thomas R, Scicchitano M,
Mirabile R, Boyce R, Zimmerman D, Grygielko E, Nold J, DeGouville
AC, Huet S, Laping N and Gellibert F: Inhibition of ALK5 signaling
induces physeal dysplasia in rats. Toxicol Pathol. 35:284–295.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Prud'homme GJ: Pathobiology of
transforming growth factor β in cancer, fibrosis and immunologic
disease, and therapeutic considerations. Lab Invest. 87:1077–1091.
2007.
|
|
12
|
Fujita T, Teramoto K, Ozaki Y, Hanaoka J,
Tezuka N, Itoh Y, Asai T, Fujino S, Kontani K and Ogasawara K:
Inhibition of transforming growth factor-β-mediated
immunosuppression in tumor-draining lymph nodes augments antitumor
responses by various immunologic cell types. Cancer Res.
69:5142–5150. 2009.
|
|
13
|
Suzawa H, Kikuchi S, Ichikawa K and Koda
A: Inhibitory action of tranilast, an anti-allergic drug, on the
release of cytokines and PGE2 from human
monocytes-macrophages. Jpn J Pharmacol. 60:85–90. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kudo-Saito C, Shirako H, Takeuchi T and
Kawakami Y: Cancer metastasis is accelerated through
immunosuppression during Snail-induced EMT of cancer cells. Cancer
Cell. 15:195–206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tanaka K, Honda M, Kuramochi T and Morioka
S: Prominent inhibitory effects of tranilast on migration and
proliferation and collagen synthesis by vascular smooth muscle
cells. Atherosclerosis. 107:179–185. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hiroi M, Onda M, Uchida E and Aimoto T:
Anti-tumor effect of N-[3,4-dimethoxycinnamoyl]-anthranilic acid
(tranilast) on experimental pancreatic cancer. J Nippon Med Sch.
69:224–234. 2002.
|
|
17
|
Izumi K, Mizokami A, Li YQ, Narimoto K,
Sugimoto K, Kadono Y, Kitagawa Y, Konaka H, Koh E, Keller ET and
Namiki M: Tranilast inhibits hormone refractory prostate cancer
cell proliferation and suppresses transforming growth factor
β1-associated osteoblastic changes. Prostate. 69:1222–1234.
2009.PubMed/NCBI
|
|
18
|
Subramaniam V, Chakrabarti R, Prud'homme
GJ and Jothy S: Tranilast inhibits cell proliferation and migration
and promotes apoptosis in murine breast cancer. Anticancer Drugs.
21:351–361. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shime H, Kariya M, Orii A, Momma C,
Kanamori T, Fukuhara K, Kusakari T, Tsuruta Y, Takakura K, Nikaido
T and Fujii S: Tranilast inhibits the proliferation of uterine
leiomyoma cells in vitro through G1 arrest associated with the
induction of p21waf1 and p53. J Clin Endocrinol Metab.
87:5610–5617. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Platten M, Wild-Bode C, Wick W, Leitlein
J, Dichgans J and Weller M: N-[3,4-dimethoxycinnamoyl]-anthranilic
acid (tranilast) inhibits transforming growth factor-β relesase and
reduces migration and invasiveness of human malignant glioma cells.
Int J Cancer. 93:53–61. 2001.
|
|
21
|
Chakrabarti R, Subramaniam V, Abdalla S,
Jothy S and Prud'homme GJ: Tranilast inhibits the growth and
metastasis of mammary carcinoma. Anticancer Drugs. 20:334–345.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kato K, Tamai H, Hayakawa H, Yamaguchi T,
Kanmatsuse K, Haze K, Aizawa T, Suzuki S, Takase S, Suzuki T,
Nishikawa H, Nakanishi S, Kato O and Nakashima M: Clinical
evaluation of tranilast on restenosis after percutaneous
transluminal coronary angioplasty (PTCA) - a double blind
placebo-controlled comparative study. J Clin Therapy Med. 12:65–85.
1996.
|
|
23
|
Zhou Y, Poczatek MH, Berecek KH and
Murphy-Ullrich JE: Thrombospondin 1 mediates angiotensin II
induction of TGF-β activation by cardiac and renal cells under both
high and low glucose conditions. Biochem Biophys Res Commun.
339:633–641. 2006.PubMed/NCBI
|
|
24
|
Miyajima A, Asano T and Hayakawa M:
Captopril restores transforming growth factor-β type II receptor
and sensitivity to transforming growth factor-β in murine renal
cell cancer cells. J Urol. 165:616–620. 2001.PubMed/NCBI
|
|
25
|
Yilmaz M and Christofori G: Mechanisms of
motility in metastasizing cells. Mol Cancer Res. 8:629–642. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Margadant C and Sonnenberg A:
Integrin-TGF-β crosstalk in fibrosis, cancer and wound healing.
EMBO Rep. 11:97–105. 2010.
|
|
27
|
Liu VC, Wong LY, Jang T, Shah AH, Park I,
Yang X, Zhang Q, Lonning S, Teicher BA and Lee C: Tumor evasion of
the immune system by converting CD4+CD25− T
cells into CD4+CD25+ T regulatory cells: role
of tumor-derived TGF-β. J Immunol. 178:2883–2892. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Conroy H, Galvin KC, Higgins SC and Mills
KH: Gene silencing of TGF-β1 enhances antitumor immunity induced
with a dendritic cell vaccine by reducing tumor-associated
regulatory T cells. Cancer Immunol Immunother. 61:425–431.
2012.
|
